| The issue
Oncology remains one of the most challenging areas for payers since it is literally in the eye of a perfect storm of expensive medications, high-cost specialized therapies, changing reimbursement rules that disrupt care and increasing cancer incidence across the US population with over 2 million new cancer cases projected in 2026 alone. The tension between rapidly evolving innovative treatments and the need for financial sustainability has reached a critical point, with cancer care costs continuing to increase for four consecutive years. The financial burden of the disease continues to rank among the top five causes of employer healthcare spending as cancer affects the working age population. Fragmented data
One key challenge is that cancer care doesn’t follow a clear, linear path. It moves through different stages and treatments that can shift quickly, causing massive cost escalation. While the trajectory follows understandable, clinical progression, the system can only identify the changes after the fact, once they appear in claims. The problem is not a sheer lack of data. Conversely, in oncology, the system relies upon fragmented medical and pharmacy claims instead of a single, clean source of relevant information that is used appropriately in real-time. As a result, high-cost patients are often identified only after their treatment path is underway and the financial impacts are already in play. For employers and plan sponsors, that delayed visibility comes at a heavy financial price, leaving little opportunity to anticipate or manage the risk in advance. What we need
When high-cost cases emerge without warning, they limit the ability to act and force organizations into a reactive position. Earlier visibility allows for a more measured and informed approach, improving both financial planning and operational response. What we lack is a consistent way to connect clinical progression with financial impact in a timeframe that aligns with strategic planning. Claims will continue to provide a reliable record of what has occurred, while clinical data will continue to offer signals about what may happen next. The challenge lies in bringing these perspectives together in a way that reflects the real-world progression of disease and treatment. — By MedCity Influencer Arnav Saxena |
No comments